Lori M.  Henderson net worth and biography

Lori Henderson Biography and Net Worth

General Counsel of Moderna

Lori Henderson is the general counsel and company secretary at Moderna Therapuetics, a clinical stage biotechnology company. 

She previously worked for Albany Molecular Research (AMRI) in the roles of vice president, general counsel and corporate secretary from 2011 to 2014, and then as SVP, general counsel and head of business development from 2014 to 2018. While there, she led legal and business development functions, proving instrumental in the organization’s overall growth.

Prior to AMRI, Henderson served as general counsel for various corporations, including Rand Worldwide and Moldflow Corporation (later acquired by Autodesk). She started her career as a corporate attorney at Goodwin Procter LLP in Boston.

Henderson earned her B.A. in business and economics from Gordon College and her J.D. from George Washington University.

What is Lori M. Henderson's net worth?

The estimated net worth of Lori M. Henderson is at least $799,306.56 as of May 27th, 2021. Ms. Henderson owns 7,501 shares of Moderna stock worth more than $799,307 as of March 29th. This net worth estimate does not reflect any other assets that Ms. Henderson may own. Learn More about Lori M. Henderson's net worth.

How do I contact Lori M. Henderson?

The corporate mailing address for Ms. Henderson and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Lori M. Henderson's contact information.

Has Lori M. Henderson been buying or selling shares of Moderna?

Lori M. Henderson has not been actively trading shares of Moderna during the last quarter. Most recently, Lori M. Henderson sold 6,600 shares of the business's stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $174.20, for a transaction totalling $1,149,720.00. Following the completion of the sale, the general counsel now directly owns 7,501 shares of the company's stock, valued at $1,306,674.20. Learn More on Lori M. Henderson's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 56 times. They sold a total of 915,065 shares worth more than $111,561,372.06. The most recent insider tranaction occured on March, 20th when Director Noubar Afeyan sold 15,000 shares worth more than $1,535,850.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 3/20/2024.

Lori M. Henderson Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2021Sell6,600$174.20$1,149,720.007,501View SEC Filing Icon  
5/25/2021Sell6,600$166.58$1,099,428.007,501View SEC Filing Icon  
5/20/2021Sell6,600$159.92$1,055,472.007,501View SEC Filing Icon  
5/18/2021Sell6,600$160.16$1,057,056.007,501View SEC Filing Icon  
5/6/2021Sell6,600$147.82$975,612.007,501View SEC Filing Icon  
5/4/2021Sell6,600$185.25$1,222,650.007,501View SEC Filing Icon  
4/29/2021Sell6,600$182.49$1,204,434.007,501View SEC Filing Icon  
4/27/2021Sell6,600$178.29$1,176,714.007,501View SEC Filing Icon  
4/22/2021Sell6,600$168.26$1,110,516.007,501View SEC Filing Icon  
4/20/2021Sell6,600$160.32$1,058,112.007,501View SEC Filing Icon  
4/15/2021Sell6,600$158.76$1,047,816.007,501View SEC Filing Icon  
4/13/2021Sell6,600$146.62$967,692.007,501View SEC Filing Icon  
4/8/2021Sell6,600$132.85$876,810.007,501View SEC Filing Icon  
4/6/2021Sell6,600$130.01$858,066.007,501View SEC Filing Icon  
4/1/2021Sell6,600$132.51$874,566.007,501View SEC Filing Icon  
3/25/2021Sell6,600$126.88$837,408.007,501View SEC Filing Icon  
3/23/2021Sell6,600$145.55$960,630.007,501View SEC Filing Icon  
3/18/2021Sell6,600$144.39$952,974.007,285View SEC Filing Icon  
3/16/2021Sell6,600$148.50$980,100.007,501View SEC Filing Icon  
3/11/2021Sell6,600$133.29$879,714.007,501View SEC Filing Icon  
10/21/2020Sell32,000$70.16$2,245,120.00View SEC Filing Icon  
6/18/2020Sell64,000$63.03$4,033,920.00View SEC Filing Icon  
5/20/2020Sell64,000$70.00$4,480,000.0064,000View SEC Filing Icon  
See Full Table

Lori M. Henderson Buying and Selling Activity at Moderna

This chart shows Lori M Henderson's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $106.56
Low: $105.95
High: $112.00

50 Day Range

MA: $98.94
Low: $85.37
High: $111.98

2 Week Range

Now: $106.56
Low: $62.55
High: $163.24

Volume

3,960,666 shs

Average Volume

4,134,107 shs

Market Capitalization

$40.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6